273 related articles for article (PubMed ID: 20952517)
1. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N; Hartog CM; Bassan R; Derigs HG; Dombret H; Greil R; Hernández-Rivas JM; Huguet F; Intermesoli T; Jourdan E; Junghanss C; Leimer L; Moreno MJ; Reichle A; Ribera J; Schmid M; Serve H; Stelljes M; Stuhlmann R; Hoelzer D;
Haematologica; 2011 Feb; 96(2):238-44. PubMed ID: 20952517
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
[TBL] [Abstract][Full Text] [Related]
3. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience.
García-Recio M; Cladera A; Bento L; Dominguez J; Ruiz de Gracia S; Sartori F; Del Campo R; García L; Ballester C; Gines J; Bargay J; Sampol A; Gutiérrez A
PLoS One; 2017; 12(6):e0179595. PubMed ID: 28665999
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
7. Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
Segot A; Raffoux E; Lengline E; Thieblemont C; Dombret H; Boissel N; Cluzeau T
Ann Hematol; 2015 Nov; 94(11):1859-63. PubMed ID: 26280395
[TBL] [Abstract][Full Text] [Related]
8. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
9. Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma.
Moser AM; Adamson PC; Gillespie AJ; Poplack DG; Balis FM
Cancer; 1999 Jan; 85(2):511-6. PubMed ID: 10023723
[TBL] [Abstract][Full Text] [Related]
10. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
[TBL] [Abstract][Full Text] [Related]
11. Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.
Holowiecka-Goral A; Hołowiecki J; Giebel S; Stella-Holowiecka B; Krawczyk-Kulis M; Kos K; Lehmann-Kopydłowska A; Dudzinski M; Hałasz M; Preisner W; Cioch M; Piszcz J
Leuk Lymphoma; 2009 Mar; 50(3):478-80. PubMed ID: 19294561
[No Abstract] [Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
Hunault-Berger M; Leguay T; Thomas X; Legrand O; Huguet F; Bonmati C; Escoffre-Barbe M; Legros L; Turlure P; Chevallier P; Larosa F; Garban F; Reman O; Rousselot P; Dhédin N; Delannoy A; Lafage-Pochitaloff M; Béné MC; Ifrah N; Dombret H;
Haematologica; 2011 Feb; 96(2):245-52. PubMed ID: 20971822
[TBL] [Abstract][Full Text] [Related]
15. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
17. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
18. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
[TBL] [Abstract][Full Text] [Related]
19. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
[TBL] [Abstract][Full Text] [Related]
20. The utility of performing the initial lumbar puncture on day 8 in remission induction therapy for childhood acute lymphoblastic leukemia: TCCSG L99-15 study.
Hasegawa D; Manabe A; Ohara A; Kikuchi A; Koh K; Kiyokawa N; Fukushima T; Ishida Y; Saito T; Hanada R; Tsuchida M;
Pediatr Blood Cancer; 2012 Jan; 58(1):23-30. PubMed ID: 21254378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
